Deeper questions on tirzepatide as a research compound — laboratory context only.
What makes tirzepatide a “unimolecular dual agonist”?
It's a single engineered peptide that activates both the GIP and GLP-1 receptors, rather than two separate compounds combined — the dual activity is built into one molecular backbone. See mechanism of action.
What's the structural basis for its dual activity?
Its backbone is derived from the native GIP sequence, modified at specific positions to additionally engage the GLP-1 receptor — see chemical structure and synthesis for the full sequence-level comparison.
How does the dual-receptor mechanism differ from a single-receptor agonist?
Research interest centers on whether engaging both incretin pathways simultaneously produces additive or synergistic metabolic-signaling effects compared to GLP-1-only agonists like semaglutide — see metabolic research.
How does it compare to retatrutide?
Tirzepatide is a dual (GIP/GLP-1) agonist; retatrutide adds a third receptor (glucagon) on top of that. See retatrutide vs tirzepatide and semaglutide vs tirzepatide for both comparisons.
How is purity documented?
Via HPLC purity and a batch certificate of analysis — V8 supplies ≥98% HPLC material. See purity testing.
Product page: Tirzepatide research vials.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.